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observations
For over a week now, America has 
been forced to look into the mirror 
to discover that it has egg on its 
presumably noble face. According 
to several recent reports in the 
Washington Post, seriously wounded 
soldiers at Walter Reed Army Hospital 
are housed in rodent infested 
facilities with holes in the ceilings 
and paint peeling off the walls—right 
in the nation’s capital, less than 
six miles from the White House. 
Meanwhile, a flood of  
reports from wounded soldiers and 
veterans elsewhere suggests that 
America, in too many instances,  
fails its wounded warriors and 
veterans in general.
Americans never tire of professing 
in words their gratitude to the 
brave men and women who fight 
the nation’s wars. Automobiles 
are adorned with $3 magnetic 
ribbons—made in China—exhorting 
the citizenry to “Support our Troops.” 
Immense praise is lavished on our 
warriors in virtually every speech by 
politicians or corporate executives 
of all ideological stripes. Finally, 
anyone who would dare question the 
administration’s war strategy and 
management is harshly accused of 
undermining the morale of the  
troops.
With all that touching, rhetorical 
support for America’s troops, what 
can account for the dissonance 
between professed sentiment and 
actual deed? One can think of at least 
two explanations: “moral hazard,” 
and callousness within the ranks of 
the army itself.
In economics, “moral hazard” 
refers to situations in which a 
decision maker does not bear the 
full negative consequences of his or 
her actions. Well insured patients 
and their doctors, for example, 
make treatment decisions under 
moral hazard, because they visit 
the cost of the chosen therapy on a 
common risk pool. To mitigate the 
social cost of moral hazard, market 
oriented American policy makers, 
notably President Bush, favour health 
insurance policies with a high degree 
of cost sharing by patients.
Moral hazard exists in the conduct 
of foreign policy as well. When those 
with the power to lead a nation into 
war are effectively shielded from 
the blood and fiscal cost of fighting 
that war, they enjoy the analogue of 
having the best health insurance. 
Should cost sharing by decision 
makers be introduced here as well?
With few exceptions, America’s 
government, financial, academic, and 
business elites are routinely shielded 
against the blood cost of war, as few 
of their offspring volunteer to serve 
in the military. Unlike in earlier wars 
in America’s history, that elite has 
been carefully shielded also from the 
negative fiscal consequences of war, 
through a series of major tax cuts. The 
war is effectively paid for with debt 
financing from Asia.
It is perhaps understandable, if not 
forgivable, that an elite so carefully 
shielded from the physical and fiscal 
consequences of war, and so self 
absorbed in accumulating wealth and 
power, will almost innocently neglect 
its wounded soldiers, taking it on 
faith that “someone” will take good 
care of them, without ever bothering 
to check whether it is so. Meanwhile, 
the incessant flood of verbal praise 
and gratitude professed for our  
troops gushes forth, because it is so 
cheap.
The army itself must shoulder part 
of the blame, and indeed several high 
ranking officials have stood down, 
including, this week, Lieutenant 
General Kevin C Kiley, the army 
surgeon general. Here a distinction 
must be made between the military’s 
medical personnel—many of them 
brave, skilful and deeply caring 
souls who accompany their buddies 
into the firefight or care for them at 
bedside in the field or at home—and 
AtlAntic crossing Uwe e reinhardt
squalour at the Walter reed Army Hospital shows how out of touch America’s elites really are
the trouble with Us military medicine
With few 
exceptions, 
america’s 
government, 
financial, academic, 
and business 
elites are routinely 
shielded against 
the blood cost of 
war, as few of their 
offspring volunteer 
to serve in the 
military
“
”
the military bureaucracy that oversees 
the care of the wounded. The sorry 
conditions of some facilities at Walter 
Reed and the mindless and often 
cruel bureaucracy routinely visited on 
wounded soldiers, for example, were 
fully known to the army sergeants in 
charge of these facilities, as well as 
to their superiors. They should have 
been known to the general in charge 
as well.
A distinction must also be made 
between the various branches of 
the military. As vice admiral Donald 
Arthur observed in testimony before 
Congress, “The marines have been 
very, very forthcoming and forward 
leaning in taking care of their own 
marine casualties.” In fact, so 
concerned are marines over the fate 
of their wounded that they station 
a small detachment of marines at 
the army run Landstuhl US Military 
Hospital in Germany for the sole 
purpose of assuring that their 
wounded comrades are treated at 
marine corps standards.
Conditions in US military medicine 
will not change until its entire 
bureaucratic system, from the top 
civilian echelon of the Pentagon on 
down through the ranks, is imbued 
with the idea that wounded soldiers 
no longer are pieces of human capital, 
so to speak, that are rented by the 
Pentagon on non-cancelable leases 
and that can be pushed around as if 
they were government property, but 
that they are fellow human beings 
worthy of our utmost gratitude and 
compassion, in deeds and in words. 
More generous budgets alone will not 
bring about that change.
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with death and disfigurement. Science fiction 
or cinematic imagery is often used to add 
potency to detailed and gruesome descrip-
tions—although no pictures were printed of 
the victims’ deformities, references such as 
“his face now resembled that of the Elephant 
Man” (Daily Star, 16 March) were used with 
effect.
Good science, bad science
TGN1412 was being developed to treat condi-
tions such as arthritis, leukaemia, and multiple 
sclerosis. In media descriptions of these condi-
tions, the terms “chronic” and “devastating” 
were instrumental in emphasising the drug’s 
potential value in eliminating suffering. By 
using these terms the media aimed to con-
vince readers that the research was worth-
while and public involvement was vital.
If the volunteers are the “heroes” of this 
story then scientists and doctors may be seen 
as the “villains.” But conflicting and conflated 
images of these groups were juxtaposed 
throughout the coverage. Recent healthcare 
scandals such as those of Shipman and Alder 
Hey have led to media descriptions of an ero-
sion of trust in medical and scientific author-
ity. Doctors’ and scientists’ actions, advice, 
and opinions are no longer considered unim-
peachable, but we still look to these profes-
sionals to develop treatments and cures.
Experts were pitted against each other: a 
researcher defended his work, saying “I don’t 
want to come across as a crazy scientist” but 
“we are not going to give up” (Mirror, 25 
March). Others questioned his enthusiasm. 
The Sunday Times quoted an expert from 
a London research institute who claimed: 
“The danger is that they are messing around 
with T regulator cells and we don’t know 
what all the T regulator subsets do.” 
Placing the drug “at the heroic edge of 
medicine,” the Guardian (17 March) ech-
oed coverage of other medical and scien-
tific advances hailed as “miracle cure” or 
“magic bullet,” bestowing the discoveries 
and their creators with supernatural or 
superhuman powers. Paradoxically, while 
“life” has become increasingly medicalised 
and expectations of science and medicine 
have increased, trust and respect for medical 
and scientific authority have allegedly dimin-
ished. When things go well doctors’ lab coats 
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“We saw human guinea pigs explode” 
l Stobbart and colleagues examine newspaper coverage of adverse events in the tGN1412 trial
The story
On 13 March 2006 eight men took part 
in a “first in man” phase 1 clinical trial of 
TGN1412, a humanised agonistic anti-CD28 
monoclonal antibody being developed by 
TeGenero to treat various diseases in which 
T cells are involved, such as chronic inflam-
matory disorders or haematological malignan-
cies. Within hours those receiving the drug 
experienced serious side effects caused by a 
severe inflammatory response, resulting in 
multiorgan failure due to a “cytokine storm,” 
for which they were managed in intensive 
care; some spent more than three months 
in hospital. Longer term effects for all of the 
volunteers remain unknown. The story broke 
in the printed media on 15 March, although 
radio news bulletins late the previous evening 
carried the first reports. Headlines were ini-
tially conservative but became more dramatic 
as the story quickly attained “scandal status.”
Analysis of press coverage
We searched LexisNexis, a database of all 
UK newspapers, for the period 14 March to 
21 April 2006, using the search term “drug 
trial.” We selected nine national newspapers 
for further exploration: the Daily Star; the 
Daily Mail, the Express; the Guardian; the Inde-
pendent; the Daily Mirror; the Observer; the Sun; 
and the Times (including Sunday editions). We 
considered various formats including news 
reports, comment and editorials, and readers’ 
published letters and emails.
The search yielded more than 200 articles 
referring to this phase 1 study. Analysis of 
press coverage yielded three main themes: 
“human tragedy,” “good science, bad sci-
ence,” and “engagement in science.” Rep-
resentative quotes are shown in the boxes 
on p 567.
Human tragedy
Initial headlines such as “Drug trial men in 
intensive care” and “Drug trial leaves six 
men seriously ill” (Daily Mail and Guardian, 
15 March) introduced relatively brief accounts 
of the events but soon began to focus on the 
volunteers and their friends and families. 
Approximately 60% of articles reviewed car-
ried a headline emphasising the “human trag-
edy,” such as the Sun’s “We saw human guinea 
pigs explode.”
The TGN1412 story fulfils many recog-
nised criteria of “newsworthiness,” including 
frequency, threshold, unambiguity, meaning-
fulness, unexpectedness, continuity, person-
alisation, and negativity. Unfolding daily, the 
story lent itself to regular updates, and per-
sonalisation of the story was used to render 
it more meaningful to the reader. Volunteers 
were stereotypically identified as students or 
low paid staff, implying vulnerability, and 
our sympathy was sought by drawing atten-
tion to their motives in volunteering for this 
research.
TGN1412 was novel; its effects were 
unexpected and were described in hor-
rific and lurid detail. Media representations 
suggested that death and disease had been 
“sequestered away from the majority of 
people’s everyday experience.” Events such 
as this fulfil an element of voyeurism and 
schadenfreude, feeding readers’ fascination 
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box 1 | Human tragedy
Detailed and emotive descriptions encouraging the reader to identify with the “victims”:
Mr Wilson, from London, said the tips of most of his toes were “basically dead” and at least half of his 
big toe had already rotted away. A keen footballer, he also faces an agonising wait to see whether the 
infection will spread, forcing doctors to amputate his feet and hands.—Daily Mail
“His head had swollen to three times its normal size. His neck was the same. It was wider than his head 
and his skin had turned a dark purple. At first none of us recognised him. His nose was spread across his 
face like it had been squashed. He had tubes in his nose and mouth and was hooked up to a machine 
helping him breathe and to a kidney dialysis machine. His eyes had been taped up and he had been 
sedated. Our fear is that he may never wake up.”—Daily Star
box 2 | Good science, bad science
Doctors and scientists presented as saviours and purveyors of medical miracles, while simultaneously 
vilified as irresponsible, uncaring and untrustworthy:
Miss Marshall, 35, called on the international scientific community for emergency assistance. Solicitor 
Ann Alexander, who is representing her critically ill boyfriend, said: “She wishes that there should be 
the widest possible attention to this tragedy in the hope that members of the scientific and medical 
community around the world will come forward with suggestions for treatment to help the doctors at 
Northwick Park who are doing a magnificent job.”—Daily Mail
We should examine the extent to which the public can trust all the parties involved. Do we trust 
TeGenero whose chief scientific officer has been very open with the media, yet which has never brought 
a product to market before? Do we trust the research company Parexel, still recruiting healthy volunteers 
for other trials? Do we trust the research ethics committee that agreed this study could take place? And 
do we trust the motives of the NHS in allowing such a contract research organisation to exist on NHS 
premises—for gain?—Independent/Independent on Sunday
box 3 | Engagement in science
Discussions of the validity of informed consent and debate concerning level of payment, inducement, 
and coercion:
Parexel—which launched the trial on behalf of the German drug company TeGenero, the manufacturers 
of TGN1412—may have breached guidelines laid down by the Association of British Pharmaceutical 
Industries over the offering of inducements. “Neither payment, nor the level thereof, should be 
mentioned in a public notice,” these state. Yet Parexel”s website for enrolling volunteers to its TGN1412 
trials clearly states that recruits would be “paid for your time and inconvenience.”—Observer
and clinical detachment are a sign of profes-
sionalism and take on almost angelic sym-
bolism, but with errors and setbacks they 
help convey a mad scientist image.
Engagement in science
Having gained the public’s attention with lurid 
and dramatic headlines of a human and per-
sonal nature, the media soon said that there 
may be a “backlash after trials catastrophe” 
even though headlines simultaneously pro-
claimed: “Tests on humans vital for our safety” 
(Independent and Mirror, 16 March).
Much of the coverage focused on pay-
ments to volunteers and whether or not this 
represented inducement. Payments for partici-
pation in clinical trials are intended to com-
pensate volunteers for their time rather than to 
induce them to participate or to minimise the 
significance of potential risk. Reports stated 
that volunteers could earn “anything between 
£100 and £3500 for taking part” and that the 
student and backpacking communities were a 
good source of volunteers.
Implications for clinical research and  
“science”
Many of the newspaper reports that we 
examined constructed a reality in which sci-
ence and scientists were out of control, the 
quest for scientific knowledge and progress 
may overshadow public safety, and our capac-
ity for innovation increasingly outstrips the 
“know-how of the relevant experts” in dealing 
with associated risks. This media-constructed 
reality is also one in which innocent and vul-
nerable members of the public were coerced 
into risking their health, and possibly their 
lives, in irresponsibly conducted research, 
and where advances in scientific capabilities 
were not matched by new and safe means of 
testing.
Such coverage could result in a decline in 
the number of volunteers for clinical research. 
The Medical Research Council, the British 
Heart Foundation, and commercial clinical 
research organisations expressed this con-
cern, and were reported as being surprised 
when inquiries about participation increased. 
It remains to be seen whether this surge in 
interest has translated to an actual increase in 
recruitment.
This incident has already taken on the 
qualities of an apocryphal event. It is referred 
to by patients both when framing questions 
about research involvement and as rationale 
for declining to participate. Organisations car-
rying out clinical trials have fielded inquiries 
from potential volunteers attracted by details 
of financial recompense; the incident is noted 
within ethical review of other, unrelated stud-
ies and is discussed at conferences, seminars, 
and research meetings. It is also referred to 
by clinicians when they explain the content of 
information documents, particularly the con-
cept of potentially unforeseen side effects.
When the Medicines and Healthcare Pro-
ducts Regulatory Agency released its final 
report on 25 May 2006, press coverage of 
the report was limited. Following the interim 
report of the Expert Scientific Group in July, 
changes had already been made to the way 
in which “first in man” phase 1 studies are 
reviewed and conducted, effectively illustrat-
ing the effects of the “controversy machine” 
whereby crisis cases and “moral panic” pre-
cipitate regulatory change. Released on 7 
December 2006, the final report of the Expert 
Scientific Group on Phase One Clinical Tri-
als was published with 22 recommendations 
to increase the safety of future clinical trials 
involving first human exposure to agents with 
potential high risk. Compared with media 
coverage of the trial itself, the report raised 
modest media interest. The full impact of the 
media coverage of the TGN1412 trial on vol-
unteer and patient participation in other trials 
remains to be determined.
L Stobbart, department of health research capacity 
development research fellow; M J Murtagh, lecturer 
in social science and public health; t Rapley, research 
associate, Institute of health and Society, Newcastle 
University, Newcastle upon tyne NE2 4hh
G a Ford, professor of pharmacology of old age, Stroke 
Research Group, Institute for ageing and health, 
Clinical Research Facility, Royal Victoria Infirmary, 
Newcastle upon tyne NE1 4LP
S J Louw, consultant physician; h Rodgers, reader in 
stroke medicine, Newcastle upon tyne hospitals NhS 
Foundation trust, Department of General Internal 
Medicine, Freeman hospital, Newcastle upon tyne 
NE7 7DN
correspondence to: M J Murtagh m.j.murtagh@newcastle.
ac.uk
competing interests: None declared.
a full version of this article with references is available on 
bmj.com
See News, p 551
